CD19.t-haNK / ImmunityBio - LARVOL DELTA

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: ImmunityBio, Inc. | N=10 ➔ 4 | Trial completion date: Dec 2028 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2028 ➔ Jul 2026; Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

QUILT-106: Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: ImmunityBio, Inc. | Recruiting ➔ Active, not recruiting | N=10 ➔ 20 | Trial completion date: Mar 2028 ➔ Oct 2027 | Trial primary completion date: Mar 2028 ➔ Oct 2027

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

QUILT-106: Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: ImmunityBio, Inc. | Trial completion date: Mar 2027 ➔ Mar 2028 | Trial primary completion date: Mar 2026 ➔ Mar 2028

First-in-human • Trial completion date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

New P2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: ImmunityBio, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

ImmunityBio, Inc…announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia. (Businesswire) - "ResQ215B builds on promising results from the Phase 1 QUILT-106 study (NCT06334991), which evaluated CD19 CAR-NK cell therapy in combination with the anti-CD20 rituximab (without ANKTIVA)....First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA and rituximab regimen to be evaluated in indolent non-Hodgkin lymphoma (iNHL), including Waldenström’s Macroglobulinemia."

Trial status • Non-Hodgkin’s Lymphoma • Waldenstrom Macroglobulinemia

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma (ImmunityBio Press Release) - "Updated follow-up demonstrates sustained complete responses with durations now extending to 15 months and ongoing, with 100% disease control observed to date...To date four patients with Waldenstrom Non-Hodgkin Lymphoma have been enrolled and all remain in clinical disease control. Two patients are evaluable for long-term follow-up and continue to demonstrate durable complete remission at 7 and 15 months and ongoing, respectively, despite receiving no additional treatment after the initial eight doses of immunotherapy....A follow-up study is being designed to test the further combination of the NK-CAR with ANKTIVA (nogapendekin alfa inbakicept; N-803), a superagonist IL-15, and rituximab to build on the success of the QUILT-106 in indolent lymphoma including Waldenström’s Macroglobulinemia."

New trial • P1 data • Non-Hodgkin’s Lymphoma • Waldenstrom Macroglobulinemia

Singe agent off-the-shelf CAR-NK (CD-19 t-haNK) cell therapy in combination with rituxumab Results in complete response in participants with waldenstrom's macroglobulinemia (ASH 2025) - P1 | "In two heavily pretreated patients with WM, an entirely chemotherapy-free, outpatient immunotherapy regimen induced profound responses, including acomplete remission achieved with CD19-targeted NK cells alone. Thesecases underscore the potential of NK cell-based combination therapy to overcomerefractory WM using the patient's immune system rather than cytotoxicchemotherapy. Updated data to be presented."

Clinical • Combination therapy • B Cell Non-Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Lymphoplasmacytic Lymphoma • Non-Hodgkin’s Lymphoma • Waldenstrom Macroglobulinemia • CD19

Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

New P2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy (ImmunityBio Press Release) - "In the first two evaluable patients with WM who were heavily pretreated, an entirely chemotherapy-free, immunotherapy regimen induced encouraging responses. Both patients tolerated the regimen with no significant toxicities. Notably, all infusions (including CAR-NK cells and cytokines) were administered in an outpatient setting. One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date."

P1 data • Non-Hodgkin’s Lymphoma • Waldenstrom Macroglobulinemia

Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: ImmunityBio, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma (Businesswire) - "Immunotherapy innovator ImmunityBio...announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL). In the QUILT 106 trial, CD19-targeted high-affinity natural killer (t-haNK) cells are being tested initially as a single agent, and after demonstrating safety, then in combination with standard NHL treatment rituximab, in participants with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. The phase 1, open label clinical study is designed to enroll up to 10 participants....Full patient enrollment in this Phase 1 study of CD19 t-haNK is currently expected in the first quarter of calendar year 2025 with topline data readout expected in the second half of the calendar year 2025."

P1 data • Trial status • Non-Hodgkin’s Lymphoma

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: ImmunityBio, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

Combination therapy • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Trial completion date: Sep 2026 ➔ Mar 2027 | Trial primary completion date: Sep 2024 ➔ Mar 2026

Combination therapy • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Apr 2023 ➔ Sep 2023

Combination therapy • Trial initiation date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc. | Initiation date: Nov 2022 ➔ Mar 2023

Combination therapy • Trial initiation date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: ImmunityBio, Inc.

Combination therapy • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. (PubMed, Cytotherapy) - "Expression of CCR7 receptor by off-the-shelf t-haNK cells improves their homing toward lymph node chemokines both in vitro and in vivo, resulting in superior tumor control."

IO biomarker • Journal • Preclinical • Hematological Malignancies • Lymphoma • Oncology • CCL19 • CCL21 • CCR7 • CD19 • PRKDC

QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: ImmunityBio, Inc.; N=18 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19